Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep is now Phase 3-ready

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jun 17, 2023 1:55pm

128 Views

Post# 35501856

RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep is now Phase 3-ready

I hope everyone appropriately rolled their eyes at this 'fud poster' comment. I've done nothing but support this company. Seems to me someone is a little touchy, and no matter how many times a $15b buyout is suggested, the current SP says it's not on the near term horizon. Fud poster, lol.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand